8.16 USD
+0.02 (+0.25%)
8.02 USD
-0.14 (-1.72%)
Overall RGLS gets a fundamental rating of 3 out of 10. We evaluated RGLS against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RGLS as it has an excellent financial health rating, but there are worries on the profitability. RGLS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year RGLS has reported negative net income.
- In the past year RGLS has reported a negative cash flow from operations.
- In the past 5 years RGLS always reported negative net income.
- RGLS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- RGLS's Return On Assets of -63.51% is on the low side compared to the rest of the industry. RGLS is outperformed by 61.22% of its industry peers.
- RGLS has a Return On Equity (-68.85%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.51% | ||
| ROE | -68.85% | ||
| ROIC | N/A |
ROA(3y)-71.13%
ROA(5y)-59.17%
ROE(3y)-95.84%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for RGLS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, RGLS has more shares outstanding
- Compared to 5 years ago, RGLS has more shares outstanding
- There is no outstanding debt for RGLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- RGLS has an Altman-Z score of 46.61. This indicates that RGLS is financially healthy and has little risk of bankruptcy at the moment.
- RGLS's Altman-Z score of 46.61 is amongst the best of the industry. RGLS outperforms 98.03% of its industry peers.
- RGLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 46.61 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 16.31 indicates that RGLS has no problem at all paying its short term obligations.
- With an excellent Current ratio value of 16.31, RGLS belongs to the best of the industry, outperforming 89.59% of the companies in the same industry.
- RGLS has a Quick Ratio of 16.31. This indicates that RGLS is financially healthy and has no problem in meeting its short term obligations.
- RGLS's Quick ratio of 16.31 is amongst the best of the industry. RGLS outperforms 89.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.31 | ||
| Quick Ratio | 16.31 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 50.00% over the past year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- RGLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.01% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.52%
EPS Next 2Y-11.37%
EPS Next 3Y22.97%
EPS Next 5Y47.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for RGLS. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as RGLS's earnings are expected to grow with 22.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.37%
EPS Next 3Y22.97%
5. Dividend
5.1 Amount
- RGLS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REGULUS THERAPEUTICS INC / RGLS FAQ
Can you provide the ChartMill fundamental rating for REGULUS THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to RGLS.
What is the valuation status for RGLS stock?
ChartMill assigns a valuation rating of 1 / 10 to REGULUS THERAPEUTICS INC (RGLS). This can be considered as Overvalued.
How profitable is REGULUS THERAPEUTICS INC (RGLS) stock?
REGULUS THERAPEUTICS INC (RGLS) has a profitability rating of 0 / 10.